Direkt zum Inhalt
Merck

SCP0167

Sigma-Aldrich

Herpes Virus Inhibitor 2

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Empirische Formel (Hill-System):
C38H59N9O13
Molekulargewicht:
849.93
UNSPSC-Code:
12352200
NACRES:
NA.32

Assay

≥95% (HPLC)

Form

lyophilized

Zusammensetzung

Peptide Content, ≥68%

Lagerbedingungen

protect from light

Lagertemp.

−20°C

Amino Acid Sequence

Tyr-Gly-Ala-Val-Val-Asn-Asp-Leu

Anwendung

The octapeptide YGAVVNDL is closely related to the nonapeptide YAGAVVNDL used to inhibit herpes virus ribonucleotide reductase.

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

J Furlong et al.
Virology, 182(2), 846-851 (1991-06-01)
The open reading frame of the large subunit (R1) of herpes simplex virus type 1 (HSV-1) ribonucleotide reductase has been positioned downstream of the phage T7 gene 10 promoter in the expression vector, pET. Transformation of this recombinant plasmid into
A Marcello et al.
Journal of chemotherapy (Florence, Italy), 7(5), 403-405 (1995-10-01)
Peptides capable of selectively disrupting protein-protein interactions that are required for viral replication represent potential agents for antiviral therapy. The first example of viral product that could be inhibited by the peptide YAGAVVNDL, targeted to the functional interaction between subunits
A Marcello et al.
Proceedings of the National Academy of Sciences of the United States of America, 91(19), 8994-8998 (1994-09-13)
Mimetic peptides capable of selectively disrupting protein-protein interactions represent potential therapeutic agents for inhibition of viral and cellular enzymes. This approach was first suggested by the observation that the peptide YAGAVVNDL, corresponding to the carboxyl-terminal 9 amino acids of the
H Paradis et al.
The Journal of biological chemistry, 263(31), 16045-16050 (1988-11-05)
Herpes simplex virus (HSV) ribonucleotide reductase activity is specifically inhibited by a synthetic peptide, Tyr-Ala-Gly-Ala-Val-Val-Asn-Asp-Leu (HSV H2-(7-15], corresponding to the carboxyl terminus of its subunit 2 (H2). In order to elucidate the mechanism of action of the nonapeptide a photoreactive
E Telford et al.
The Journal of general virology, 71 ( Pt 6), 1373-1378 (1990-06-01)
The synthetic nonapeptide YAGAVVNDL [identical to the nine carboxy-terminal amino acids of the small subunit of herpes simplex virus (HSV)-encoded ribonucleotide reductase (RR)] was found to inhibit the RR activity induced by equine herpesvirus type 1 subtype 1 (EHV-1). Parallel

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.